Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
15 September 2023 - 6:00AM
Zealand Pharma Increases its Share Capital as a Consequence of
Exercise of Employee Warrants
Company announcement – No. 34 / 2023
Zealand Pharma Increases its Share Capital as a
Consequence of Exercise of Employee Warrants
Copenhagen, Denmark, September 14, 2023 –
Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50
78), a Copenhagen-based biotechnology company focused on the
discovery and development of innovative peptide-based medicines,
has increased its share capital by a nominal amount of DKK 20,102
divided into 20,102 new shares with a nominal value of DKK 1 each.
The increase is a consequence of the exercise of warrants granted
under several of Zealand Pharma's employee warrant programs.
Employee warrant programs are part of Zealand Pharma’s incentive
scheme, and each warrant gives the owner the right to subscribe for
one new, Zealand Pharma share at a prespecified price, the exercise
price, in specific predefined time periods before expiration. For a
more detailed description of Zealand Pharma’s warrant programs, see
the company’s Articles of Association, which are available on the
website: www.zealandpharma.com.
The exercise price was DKK 127.00 per share for 2,282 of the new
shares, DKK 224.40 per share for 12,820 of the new shares and DKK
220.00 per share for 5,000 of new shares. The total proceeds to
Zealand from the capital increase amount to DKK 4,266,622.
The new shares give rights to dividend and other rights from the
time of the warrant holder's exercise notice. Each new share
carries one vote at Zealand Pharma’s general meetings. Zealand
Pharma has only one class of shares.
The new shares will be listed on Nasdaq Copenhagen after
registration of the capital increase with the Danish Business
Authority. Following registration of the new shares, the share
capital of Zealand Pharma will be nominal DKK 58,677,438 divided
into 58,677,438 shares with a nominal value of DKK 1 each.
A full copy of the amended Articles of Association can be found
at https://www.zealandpharma.com once registered with the Danish
Business Authority.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology
company focused on the discovery and development of peptide-based
medicines. More than 10 drug candidates invented by Zealand have
advanced into clinical development, of which two have reached the
market and three candidates are in late-stage development. The
company has development and partnerships with a number of blue-chip
pharma companies as well as commercial partnerships for its
marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen,
Denmark, with a presence in the U.S. that includes Boston. For more
information about Zealand’s business and activities, please
visit www.zealandpharma.com.
Contact:
Adam Lange (Investors) Investor
Relations Officer Zealand Pharma akl@zealandpharma.com |
Anna Krassowska, PhD (Investors and
Media) Vice President, Investor Relations & Corporate
Communications Zealand Pharma ank@zealandpharma.com |
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
From Sep 2023 to Sep 2024